Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Royal Marsden NHS Foundation Trust
MR imaging has the potential to improve both the localisation of pan-LN treatments and the subsequent treatment delivery using MR-linac technology. The MIRABELLE study will apply the MR sequences developed in LN-negative volunteers/patients to the context of node-positive breast cancer patients with the aim of reducing the delineated nodal volume thereby facilitating dose-escalation to involved LNs. The benefit of using MRI for LN localisation as compared to conventional CT imaging will be investigated by determining whether a higher dose can be delivered using MRI- as compared to CT-based delineation. Any increase in dose will be deemed a success as this has potential to improve tumour control. In addition, inter-observer errors in outlining will be explored to investigate whether these are reduced using MRI. Reduced inter-observer errors would result in smaller margins for error such that less normal tissue could be irradiated.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years
Female or male
Invasive carcinoma of the breast (left or right-sided)
cT1-T4,N3,M0-1 disease
Due to proceed to primary treatment (chemo, surgery, radiotherapy and/or endocrine therapy)
Histopathological involvement of axillary lymph nodes confirmed on FNA or Bx
Likely to undergo locoregional radiotherapy as part of their breast cancer management
You may not be if
Implanted pacemakers and/or pacing wires
Cochlear implants
Programmable hydrocephalus shunts
Implanted neurostimulation systems
Implanted drug infusion pumps
Ferromagnetic implants
Claustrophobia
Clareo Health | MR-guided RAdiotherapy to Breast With Dose Escalation to regionaL Lymph NodEs